1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on the Etiology of Sporadic Early-Onset Cancers (U01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI). This NOFO invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies.
This could include early-onset endometrial cancers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: State governments, public housing authorities/Indian housing authorities, city or township governments, public and State controlled institutions of higher education, special district governments, Native American tribal organizations (other than Federally recognized tribal governments), for-profit organizations other than small businesses, small businesses, Native American tribal governments (Federally recognized), nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, independent school districts, private institutions of higher education, county governments. Confirm the full requirements in the official notice before applying.
Applications for Research on the Etiology of Sporadic Early-Onset Cancers (U01 Clinical Trial Optional) are due October 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on the Etiology of Sporadic Early-Onset Cancers (U01 Clinical Trial Optional) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article